Improved strategic decision making and patient outcomes in Oncology

IMS Health helps clients establish Real-World Evidence Solutions (RWES) to support product value, safety, access and pricing for all healthcare stakeholders. We can help you capture value from solutions with the right data, advanced analytics and technology.

- **500+ million** anonymous longitudinal patient data records including EMR, claims data, hospital data and lab tests in 25+ markets
- **Rich oncology information assets** cover 3 continents, 13+ countries and 25+ primary cancers
- **Partnerships** and **data sourcing capabilities** to get the data to meet your needs
- **Leading edge technology and analytics** to enhance understanding of patient outcomes, healthcare costs, pharmacoepidemiology, drug safety and product value
- **Experts in 20+ markets** with deep expertise in RWE, HTA and payer requirements to translate insights into actions
- **Asia-Pacific hubs** in Singapore, China and Japan to service local evidence needs

**First HCC Registry in Asia**

- **Coverage**: 35 clinical sites across 9 key Asian markets with 2,500 patients
- **Partnership with NCCS, SCRI and Asian HCC Physician Network**
- **Anonymous** data captured
- **Facilitate informed decision-making** by healthcare stakeholders

*National Cancer Centre Singapore (NCCS), SingaporeClinical Research Institute (SCRI), Hepatocellular Carcinoma (HCC)*

For more information, please email RWEinfo@imshealth.com

Uncovering insights from real-world data